A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
== Chemistry == 1S-LSD belongs to the lysergamide class of compounds, which are characterized by the ergoline structure derived from lysergic acid. The compound is closely related to LSD and 1P-LSD but differs by the addition of a trimethylsilyl group on the propionyl chain. The nitrogen atom in the polycyclic indole group of the ergoline structure is a common site for chemical modifications, as it is highly reactive and accessible for various reactions. These modifications often include alkylations, acylations, Mannich reactions, and Michael additions. Such alterations are frequently explored in the synthesis of new analogues to modify pharmacological properties or evade legal controls. The addition of the trimethylsilyl group in 1S-LSD represents a strategic modification designed to keep the substance outside the coverage of Germany's New Psychoactive Substances Act (NpSG). Despite these changes, 1S-LSD likely retains a pharmacological profile similar to that of LSD, acting primarily as a serotonergic hallucinogen.
Isovaline is a rare amino acid found in the Murchison meteorite, which landed in Australia in 1969. The discovery of isovaline in the biosphere demonstrates an extraterrestrial origin of amino acids and has been linked to the homochirality of life on Earth, suggesting a role in the origin of life. Isovaline is an isomer of the common amino acid valine, with the position of one methyl group shifted slightly (from position 3 to position 2). The structure of isovaline is also somewhat similar to the amino acids GABA and glycine, the chief inhibitory neurotransmitters in the mammalian central nervous system. Isovaline acts as an analgesic in mice by activating peripheral GABAB receptors. In a mouse model of osteoarthritis isovaline restored mobility, suggesting inhibition of nociception by isovaline in the synovial membrane of the mouse knee. Isovaline does not cross the blood–brain barrier and does not enter into the brain or spinal cord. Isovaline acts downstream to the cyclooxygenase system that NSAIDs inhibit, suggesting a means to avoid adverse effects such as irritation of the gastrointestinal system.
By the early 2000s most lichen phylogenies analysed 3–5 genes (a few thousand base pairs in total). Frequently used loci were nuLSU rDNA, ITS (the standard barcode), and protein-coding fragments such as RPB1/2 or β-tubulin. Multilocus trees clarified family- and order-level relationships. They confirmed that almost all lichen-forming ascomycetes fall into three classes: Lecanoromycetes (the largest, e.g., Parmeliaceae, Lecanoraceae, Physciaceae), Eurotiomycetes (e.g., some Verrucaria), and Sordariomycetes (e.g., Graphidaceae). A small minority occur in the Basidiomycota (several agaric and clavarioid orders) or in smaller ascomycete classes. Thus molecular work placed lichens securely within the fungal tree, as Santesson had anticipated. The results prompted extensive revision; orders and families were reorganized to remove polyphyletic groups. For example, the pre-molecular 'Lecanorales' was divided into several orders (Lecanorales, Peltigerales, Teloschistales, etc.) after DNA data showed that superficially similar fruiting bodies did not imply close relationship. By the late 2000s a molecular phylogeny was routine in new taxonomic studies. Traditional methods remained important alongside molecular approaches. Morphology and chemistry remained essential: they guided sampling, framed hypotheses, and provided the diagnostic traits needed to circumscribe taxa. Many new species—particularly from biodiversity-rich regions—were still described from morphology alone or with a single DNA barcode.
Sources: en.wikipedia.org
==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).
=== Pharmacodynamics === Levomethadone has approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity. Accordingly, it is about twice as potent as methadone by weight and its effects are virtually identical in comparison. In addition to its activity at the opioid receptors, levomethadone has been found to act as a weak competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor complex and as a potent noncompetitive antagonist of the α3β4 nicotinic acetylcholine (nACh) receptor.
Using purified proteins on substrates including artificial lipid bilayers and flow-based adhesion assays, his lab discovered the first heterophilic (like-unlike) receptor–counter-receptor adhesion pairs in all of cell biology, including CD2–LFA-3 and LFA-1–ICAM. The LFA-1–ICAM interaction required Mg2+, and explained the Mg2+-dependence of cell adhesion in antigen recognition. Subsequently, Springer structurally resolved the LFA-1–ICAM-1 interaction, with Mg2+ at the ligand-binding interface.
Sources: en.wikipedia.org
== Rivalries == The club's fans share a fierce and often violent rivalry with the supporters of Chemie Leipzig. When both teams met in the quarter finals of the Sachsenpokal in 2016, German daily newspaper Die Welt called the match the "German hooligan summit". An additional reason for the enmity between some fan groups (namely their ultras) is a political one. Whereas certain Chemie fan clubs express left-wing and anti-fascist political views, Lok has vocal supporters from the right and far-right of the political spectrum. Lok also have lesser local rivalry with RB Leipzig.
The oldest definitive evidence for fire making (i.e. igniting a new fire) dates to ~400,000 years ago at a Neanderthal site in Suffolk, England, where burnt soil was found along with fire-cracked flint handaxes and two fragments of iron pyrite, used to strike sparks with flint. At other sites in France dating from 50,000 years ago onwards, dozens of Neanderthal hand axes exhibit use-wear traces suggesting they were struck with pyrite to produce sparks. Ötzi, a well-preserved natural mummy of a man who lived in the Ötztal Alps between 3350 and 3105 BCE, carried fire-making material in the form of tinder fungus with flint and pyrite for creating sparks. The Kaurna people of South Australia have used pyrite with flintstone and a form of tinder made of stringybark as a traditional method of starting fires. Pyrite has been used since classical times to manufacture copperas (ferrous sulfate). Iron pyrite was heaped up and allowed to weather (an example of an early form of heap leaching). The acidic runoff from the heap was then boiled with iron to produce iron sulfate. In the 15th century, new methods of such leaching began to replace the burning of sulfur as a source of sulfuric acid. By the 19th century it had become the dominant method. Marcasite jewelry, using small faceted pieces of pyrite, often set in silver, has been made since ancient times and was popular in the Victorian era.
== Function == Only a few methanogenic archaea have cell walls composed of pseudopeptidoglycan. This component functions much like peptidoglycan in a bacterial cell. Pseudopeptidoglycan is used by the archaeal cell to determine its shape and provide structure to the cell. It is also used to protect the cell from undesired molecules or anything harmful in its environment.
Allele-specific PCR or The amplification refractory mutation system (ARMS): a diagnostic or cloning technique based on single-nucleotide variations (SNVs not to be confused with SNPs) (single-base differences in a patient). Any mutation involving single base change can be detected by this system. It requires prior knowledge of a DNA sequence, including differences between alleles, and uses primers whose 3' ends encompass the SNV (base pair buffer around SNV usually incorporated). PCR amplification under stringent conditions is much less efficient in the presence of a mismatch between template and primer, so successful amplification with an SNP-specific primer signals presence of the specific SNP or small deletions in a sequence. See SNP genotyping for more information. Arbitrarily amplified DNA is a family of DNA profiling methods that use arbitrary primers to amplify DNA of unknown sequence with the PCR reaction. They include random amplified polymorphic DNA (RAPD), arbitrarily primed PCR (AP-PCR), and DNA amplification fingerprinting (DAF). The arbitrary nature of the primers used in these methods target anonymous regions in a genome or engineered construct generating unique genetic fingerprints. This sets these techniques apart from standard PCR methodologies that require knowledge of the target sequence. Assembly PCR or Polymerase Cycling Assembly (PCA): artificial synthesis of long DNA sequences by performing PCR on a pool of long oligonucleotides with short overlapping segments.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.